We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEvgen Pharma Share News (EVG)

Share Price Information for Evgen Pharma (EVG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.80
Bid: 0.75
Ask: 0.85
Change: 0.00 (0.00%)
Spread: 0.10 (13.333%)
Open: 0.80
High: 0.80
Low: 0.80
Prev. Close: 0.80
EVG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Synectics loss narrows; Active Energy loss widens

Mon, 14th Jun 2021 13:19

(Alliance News) - The following is a round-up of updates by London-listed companies issued on Monday and not separately reported by Alliance News:

----------

Synectics PLC - Sheffield, England-based security systems services company - Says trading in the six months to the end of May continued at similar levels as last year, with estimated operating loss of GBP800,000 versus GBP2.0 million in the first half of the prior financial year. This follows action taken last year to reduce Synectics' operating cost base. Revenue declined 4.3% to GBP22 million from GBP23 million year-on-year.

----------

Inspirit Energy Holdings PLC - London-based heat and power appliances manufacturer - Says it has been working with its engineering partners on the details of the new waste heat recovery systems for the application on the Volvo marine engine. Details of the electrical and the main mechanical systems are near completion, Inspirit says. It expects that by the end of 2021, all major items of the waste heat recovery system will be complete, with a view to having the designs for a full working prototype that can be put into manufacture. Inspirit is working with marine engine maker Volvo Penta.

----------

Active Energy Group PLC - London-based renewable energy company - Reports USD9.0 million of pretax loss from continuing operations in 2020, widened from USD3.3 million the year before. This is the result of USD4.8 million of impairment charges recorded in 2020 versus no such charges the year earlier. They relate to the impairment of non-core assets and the decision to focus resources on commercialisation of CoalSwitch. Revenue slips 5.2% to USD1.8 million from USD1.9 million.

----------

Scirocco Energy PLC - seeking investments in production and development opportunities within the European energy market - Reports widened pretax loss of GBP3.3 million for 2020 compared to GBP2.6 million the year before, amid higher administrative expenses. Has no revenue in either year. Scirocco notes continued focus on cost discipline, including salary sacrifices and implementation of option based remuneration for executives. Also proposes investment in Energy Acquisitions Group Ltd, a specialist acquisition and operating vehicle in the sustainable energy sector. The investment in conditional on shareholder approval for a change in the company's investing policy. This investment of GBP1.2 million will be funded from current cash resources. EAG will use the funds to buy Greenan Generation Ltd, which has an anaerobic digestion renewable energy plant in Northern Ireland.

----------

Helium One Ltd - helium exploration and development company - Says three well exploration programme targeting shallow trap structures to a maximum depth of 1,200 metres has started at Rukwa project. Each well will take about one month to complete. "We look forward to announcing results of our first well at what is a potentially transformative time for the company," says CEO David Minchin. Scirocco Energy notes the update by Helium One, in which it has 1.2% holding.

----------

Nostra Terra Oil & Gas Co PLC - oil & gas exploration and production company focussed on the US state of Texas - Reports revenue for 2020 of USD1.0 million, down from USD1.8 million recorded in 2019. Production for the year was 29,583 barrels of oil, lower than 33,179 barrels of oil in 2019. Despite that, pretax loss narrowed to USD1.3 million from USD1.7 million year-on-year, as administrative expenses were reduced to USD896,000 from USD1.6 million. "2020 was a very challenging year for businesses around the world, with oil & gas companies amongst the worst hit," notes Chief Executive Matt Lofgran.

----------

Distil PLC - London-based owner of premium drinks brands - Says turnover in 2020 increased 48% to GBP3.6 million from GBP2.4 million, as it increased export sales of existing brands by 81% year-on-year. Advertising & promotion spend increased 61% to GBP1.1 million from GBP665,000 the year prior and other administrative expenses increased 9% to GBP651,000 from GBP597,000 year-on-year. Despite the increased spending, pretax profit rose to GBP243,000 from GBP182,000.

----------

Tanfield Group PLC - UK-based investment firm - Reports pretax loss from operations of GBP697,000 for 2020, widened from GBP317,000 posted the year before, due to higher interest costs and an increase in legal fees due to ongoing US and UK court proceedings. Tanfield's 51% joint venture partner Xtreme Manufacturing LLC, via its subsidiary SKL Holdings LLC and Snorkel International, filed a summons and complaint against Tanfield and its subsidiary HBWP Inc. Tanfield said it remains "disappointed" that a resolution has not been possible and therefore continues to seek advice and defend its position.

----------

Thalassa Holdings Ltd - invests in real estate, fintech and robotics - Reports swing to pretax profit of USD1.6 million in 2020 from loss of USD3.8 million, despite revenue falling to USD55,855 from USD170,357. The swing to pretax profit comes amid reduction in administrative expenses to USD3.2 million from USD4.2 million year-on-year and the booking of finance income of USD3.6 million versus finance expense of USD640,117 the year before.

----------

SourceBio International PLC - Nottingham, England-based provider of laboratory services - Continues to trade well since the end of 2020 with revenue, earnings and cash generation in the year-to-date significantly ahead of the equivalent period last year. Going forward, expects peak levels of revenue and earnings to be generated from anticipated high levels of travel-related virus testing in the coming months. SourceBio says it remains optimistic for the remainder of the year and beyond as a result.

----------

Evgen Pharma PLC - Liverpool-based clinical stage drug development company - Reports clinical trial plans for SFX-01 in glioblastoma. Glioma is the most common form of brain tumour. Previously the company reported that data generated by University L'Aquila showed that with pre-clinical subcutaneous and orthotopic models, SFX-01 produced tumour shrinkage and significantly extended survival times. Evgen now reports that data from these experiments have been reproduced with very similar results at the University of Auckland using cells generated from freshly extracted patient glioblastoma tissue, rather than the standard glioblastoma cell lines established many decades previously. Going forward, Evgen says plans for a phase II glioblastoma clinical trial with an adaptive design are progressing with a scheduled start in the first half of 2022.

Separately, Evgen reports new preclinical data which shows SFX-01 may be of benefit to metastatic breast cancer patients who have become resistant to CDK4/6 inhibitors. Should these results be reinforced, Evgen will pursue a phase II placebo-controlled study a in second-line estrogen receptor positive metastatic breast cancer treatment of patients who have failed on CDK4/6 inhibitors. Such a trial could commence in 2022.

----------

nmcn PLC - Nottinghamshire-based construction engineering company - Says it is now in bilateral discussions with a party to conclude a refinancing. The company says it is working towards reaching a position where the refinancing will be announced within the next week enabling nmcn to address its current significant working capital strain. Should the refinancing not be successfully concluded the group will have to consider its remaining options.

----------

Apollon Formularies PLC - London-based medical cannabis company - Says Apollon Formularies Jamaica has signed a long-term lease for its first International Cancer Institute in the Jamaican capital of Kingston. The new facility will specialise in complementary and alternative medical treatments for cancer patients. These treatments will include Apollon's medical cannabis products.

----------

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
4 Apr 2024 17:24

TRADING UPDATES: Northcoders launches bootcamp; Schroder invests

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
19 Mar 2024 19:47

EARNINGS AND TRADING: Ten Lifestyle sees profit up but sales flat

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
27 Feb 2024 15:59

Evgen Pharma finds evidence of SFX-01 activity in colon cancer models

(Alliance News) - Evgen Pharma PLC on Tuesday said it found further evidence of SFX-01 activity in models of colon cancer.

Read more
19 Feb 2024 11:45

Evgen Pharma shares up on studies into SFX-01 product progressing well

(Alliance News) - Evgen Pharma PLC on Monday said the studies into its SFX-01 product were progressing positively regarding its activity in Glioblastoma cells.

Read more
9 Feb 2024 18:53

TRADING UPDATES: Apax opts against lifting offer; DCI enters loan deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
9 Feb 2024 17:02

LONDON MARKET CLOSE: FTSE 100 falls at end of tepid week

(Alliance News) - Stock prices in London closed lower on Friday, with the FTSE 100's losing streak extending to three days, as sentiment in Europe remains tetchy despite a largely stellar start to the day in New York.

Read more
16 Jan 2024 18:59

IN BRIEF: Evgen partner raises USD17.4 million to support pipeline

Evgen Pharma PLC - clinical stage drug development company developing sulforaphane-based medicines - Notes that its partner in autism spectrum disorder and other neurodevelopmental disorders Stalicla SA has announced that it has raised USD17.4 million, inclusive of a credit facility. This is to to support programmes on STP1, Stalicla's first asset in ASD, and a further asset in substance use disorders together with a biosampling and patient identification study in ASD. Evgen says it continues to work with Stalicla on delivery of a milestone payment for SFX-01 (Stalicla's STP2). Evgen says both parties are engaged in analysis and interpretation of Evgen's recent Phase 1b healthy volunteer PK/PD study and the implications for a future phase 2 trial in ASD. Evgen says it will provide updates on the status of the programme in "due course" and has not anticipated any milestone payments from Stalicla in its financial forecasting.

Read more
22 Dec 2023 18:06

IN BRIEF: Evgen appoints Toni Hanninen as permanent CFO

Evgen Pharma PLC - clinical stage drug development company developing sulforaphane-based medicines - Appoints Toni Hanninen as permanent chief financial officer, adding that he will now join the board as a director. Hanninen was appointed as interim CFO in September, having previously worked at Faron Pharmaceuticals Ltd. His permanent appointment becomes effective from January 1. Evgen also confirms that non-executive director, Susan Clement-Davies, will be retiring from the board.

Read more
31 Oct 2023 14:38

TRADING UPDATES: Acuity RM wins contract; Georgia Capital ups earnings

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday, and not separately reported by Alliance News:

Read more
26 Oct 2023 11:08

Evgen upbeat on start of glioblastoma research project

(Sharecast News) - Clinical-stage drug developer Evgen Pharma announced on Thursday that it has partnered with Dr Marjolein Geurts, a neuro-oncologist at Erasmus University Medical Centre, to start a ground-breaking research initiative in glioblastoma.

Read more
19 Oct 2023 19:39

IN BRIEF: Evgen showcases importance of new enteric-coated formulation

Evgen Pharma PLC - Cheshire, England-based clinical stage drug developer - Highlights article published in respected industry publication the Medicine Maker, by its Chief Business Officer, Helen Kuhlman. The article, entitled the Sulforaphane Promise, focuses on the recent study of Evgen's new enteric-coated tablet formulation, and why enteric coatings are of particular importance for a stabilised complex such as SFX-01 that releases highly biologically active sulforaphane. The SFX-01 complex is vulnerable to breakdown in acid conditions and the enteric coat prevents acid attack in the stomach, releasing the drug in the ideal region - the small bowel. It also discusses the pharmacodynamic and pharmacokinetic data from the recent study, demonstrating the improvements of the tablet formulation over previous formulations of SFX-01.

Read more
5 Sep 2023 14:22

Evgen Pharma hires interim CFO from Faron, chair to retire this month

(Alliance News) - Evgen Pharma on Tuesday said Non-Executive Chair Barry Clare will retire at its next board meeting, and announced the hiring of interim Chief Financial Officer Toni Hanninen.

Read more
15 Aug 2023 10:01

Evgen Pharma says trial shows new SFX-01 drug formulation is safe

(Alliance News) - Evgen Pharma PLC on Tuesday said final data from a trial of its SFX-01 therapy has shown a new formulation of the drug is safe.

Read more
2 Aug 2023 10:28

IN BRIEF: Evgen Pharma shares drop on ending of license agreement

Evgen Pharma PLC - Cheshire, England-based clinical stage drug development company focused on developing sulforaphane-based medicines - Terminates the patent and know-how license agreement for its Sulforadex sulforaphane stabilisation technology with partner JuvLife Ltd. The exclusive rights will be returned in the final quarter of 2023. The already received upfront payment is non-refundable.

Read more
2 Aug 2023 10:09

AIM WINNERS & LOSERS: Deltex plummets on return to AIM; Blancco rises

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.